RAPT

RAPT

USD

RAPT Therapeutics Inc. Common Stock

$28.500-0.050 (-0.175%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$28.550

最高

$29.605

最低

$28.190

交易量

0.43M

公司基本面

市值

708.8M

行業

生物科技

國家

United States

交易統計

平均交易量

0.36M

交易所

NGM

貨幣

USD

52週範圍

最低 $5.664當前 $28.500最高 $42.392

相關新聞

GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

查看更多
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $48 to $72.

查看更多
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics with a Buy and raises the price target from $27 to $72.

查看更多
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics with a Buy rating and announces Price Target of $70.

查看更多
Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70
GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and

查看更多
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $48

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $38 to $48.

Analyst Upgrades

Barclays Maintains Overweight on RAPT Therapeutics, Raises Price Target to $58

Barclays analyst Etzer Darout maintains RAPT Therapeutics with a Overweight and raises the price target from $35 to $58.